RxDoctor Payments Data

Talin Dadoyan, MD

Psychiatry · Sherman Oaks, CANPI 1801908397

Payments from drug & device makers

$1,111in general payments, 2019–2025

Across 38 payments — averaging $29.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$377
  • Johnson & Johnson$278
  • Axsome Therapeutics, Inc.$150
  • Sun Pharmaceutical Industries Inc.$62
  • Lundbeck LLC$43
  • Otsuka America Pharmaceutical, Inc.$43
  • plus $159 from 6 others

What the payments were for

  • Food & beverage$1,111100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,111 in reported general payments places this provider in the 75th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$343,017
Medicare patients
818
Services billed
3,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate45$130,037
IngrezzaValbenazine Tosylate16$119,690
Divalproex Sodium364$19,957
Clozapine286$14,643
Aripiprazole93$5,866
Olanzapine326$5,791
Temazepam107$5,726
Chlorpromazine Hcl19$4,215
Valproic AcidValproic Acid (As Sodium Salt)86$4,105
Clozapine OdtClozapine30$3,609
Quetiapine Fumarate236$3,374
Risperidone312$3,369
Oxcarbazepine57$2,538
Venlafaxine Hcl ErVenlafaxine Hcl38$2,388
Benztropine Mesylate169$2,378

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$278$130,03745 claims
Neurocrine Biosciences, Inc.Ingrezza$377$119,69016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Sherman Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →